 | • レポートコード：TPM-B04540 • 出版社/出版日：Transparency Market Research / 2017年10月 • レポート形態：英文、PDF、214ページ • 納品方法：Eメール • 産業分類：製薬・医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、片頭痛治療薬の世界市場について調べ、片頭痛治療薬の世界規模、市場動向、市場環境、治療法別分析、投与方法別分析、流通経路別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、バリューチェーン分析、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・片頭痛治療薬の世界市場動向 ・片頭痛治療薬の世界市場環境 ・片頭痛治療薬のバリューチェーン分析 ・片頭痛治療薬の世界市場規模 ・片頭痛治療薬の世界市場規模：治療法別 ・片頭痛治療薬の世界市場規模：投与方法別 ・片頭痛治療薬の世界市場規模：流通経路別 ・片頭痛治療薬の世界市場：地域別市場規模・分析 ・片頭痛治療薬の北米市場規模・予測 ・片頭痛治療薬のアメリカ市場規模・予測 ・片頭痛治療薬の中南米市場規模・予測 ・片頭痛治療薬のヨーロッパ市場規模・予測 ・片頭痛治療薬のアジア市場規模・予測 ・片頭痛治療薬の日本市場規模・予測 ・片頭痛治療薬の中国市場規模・予測 ・片頭痛治療薬のインド市場規模・予測 ・片頭痛治療薬の中東市場規模・予測 ・片頭痛治療薬のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global Migraine Drugs Market: Scope and Methodology
This report on the global migraine drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global migraine drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global migraine drugs market.
Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different types of treatments & drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of migraine drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Migraine Drugs Market: Segmentation
Migraine is type of headache, estimated to affect 12 to 14.7% of population across the globe. According to international as well regional guidelines it is categorized by frequency and nature of attack into episodic migraine and chronic migraine. Abortive and prophylactic are the two treatments offered for migraine relief. Abortive treatment which is given to abort acute attack of migraine include medication such as triptans, ergot alkoids and others. While prophylactic treatment is recommended to patients with chronic migraine to prevent migraine attacks using medications such as botulinum toxin, topiramate and other drugs.
Based on treatment, the global migraine drugs market has been segmented into abortive and prophylactic. These treatments segments are further classified based on the drug class such as abortive treatment is classified into triptans, ergot alkoids, and others while prophylactic treatment is segmented into botulinum toxin, topiramate and others. Abortive treatment segment is projected to hold dominant share of global migraine drugs market while prophylactic treatment segment is likely to register steady growth during the forecast period from 2017 to 2025.
Based on route of administration, the global migraine drugs market is segmented into oral, injectable and others. Others segment of route of administration include nasal sprays, transdermal patches, etc. Low cost and vast availability of orally administrable drugs is projected to contribute for dominating share of oral segment of route of administration.
Based on the distribution channel, the global migraine drugs market is segmented into retail pharmacies, hospital pharmacies and others. Ever increasing number of retail pharmacies, self-medication with widely available OTC migraine abortive drugs is attributed for the significant share of the segment in the global market.
Migraine Drugs Market: Geographical and Competitive Dynamics
Geographically, the global migraine drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.
The report also profiles major players in the migraine drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca Plc., Allergan Plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Eli Lilly & Co. Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceuticals Inc., Zosano Pharma Corporation, Alder BioPharmaceuticals Inc., and others.
The global migraine drugs market has been segmented as below:
Global Migraine Drugs Market, by Treatment
Abortive
Triptans
Ergot Alkaloids
Others
Prophylactic
Botulinum Toxin
Topiramate
Others
Global Migraine Drugs Market, by Route of Administration
Oral
Injectable
Others (Nasal Spray, Transdermal Patch, etc.)
Global Migraine Drugs Market, by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Others (Online Pharmacies, Drug Stores, etc.)
Global Migraine Drugs Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Israel
Rest of Middle East and Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Migraine Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. High prevalence of migraine and increasing transition from episodic to chronic migraine
4.3.1.2. Increasing investment in R&D and promising pipeline of novel drugs
4.3.1.3. Aging population and increasing proportion of female population
4.3.1.4. Increasing awareness among patients and high promotional investment by key players
4.3.2. Restraints
4.3.2.1. Fragmented Market with vast availability of generic drugs
4.3.2.2. Ongoing investment in alternative therapies
4.3.3. Opportunities
4.3.4. Trends
4.4. Migraine Drugs Market Analysis and Forecast, 2017 – 2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s five forces analysis
4.6. Value Chain Analysis
4.7. Global Prevalence of Migraine
4.8. Pipeline Analysis
4.8.1. Pipeline Analysis: Migraine Treatment Drugs
4.8.2. Pipeline Analysis: Migraine Treatment Devices
4.9. Market Outlook
5. Global Migraine Drugs Market Analysis and Forecasts, By Treatment
5.1. Introduction & Definition
5.2. Key Findings
5.3. Market Size (US$ Mn) Forecast, By Treatment
5.3.1. Abortive
5.3.1.1. Triptans
5.3.1.2. Ergot Alkaloids
5.3.1.3. Others
5.3.2. Prophylactic
5.3.2.1. Botulinum Toxin
5.3.2.2. Topiramate
5.3.2.3. Others
5.4. New (Pipeline) Migraine Drugs Market Revenue (US$) Forecast, 2017-2025
5.5. Market Attractiveness, By Treatment
5.6. Key Trends
6. Global Migraine Drugs Market Analysis and Forecasts, By Route of Administration
6.1. Introduction & Definition
6.2. Key Findings
6.3. Market Size (US$ Mn) Forecast, By Route of Administration
6.3.1. Oral
6.3.2. Injectable
6.3.3. Other
6.4. Market Attractiveness, By Route of Administration
6.5. Key Trends
7. Global Migraine Drugs Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings
7.3. Market Size (US$ Mn) Forecast, By Distribution Chanel
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Market Attractiveness, By Distribution Channel
7.5. Key Trends
8. Global Migraine Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Global Market Scenario
8.3. Market Size (US$ Mn) Forecast, By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Attractiveness, By Region
8.5. Key Trends, By Region
9. North America Migraine Drugs Market Analysis and Forecast
9.1. Key Findings
9.2. Market Size (US$ Mn) Forecast, By Treatment
9.2.1. Abortive
9.2.1.1. Triptans
9.2.1.2. Ergot Alkaloids
9.2.1.3. Others
9.2.2. Prophylactic
9.2.2.1. Botulinum Toxin
9.2.2.2. Topiramate
9.2.2.3. Others
9.3. Market Size (US$ Mn) Forecast, By Route of Administration
9.3.1. Oral
9.3.2. Injectable
9.3.3. Others
9.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
9.4.1. Retail Pharmacies
9.4.2. Hospital Pharmacies
9.4.3. Others
9.5. Market Size by Value (US$ Mn) Forecast, By Country
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By Route of Administration
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe Migraine Drugs Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, By Treatment
10.2.1. Abortive
10.2.1.1. Triptans
10.2.1.2. Ergot Alkaloids
10.2.1.3. Others
10.2.2. Prophylactic
10.2.2.1. Botulinum Toxin
10.2.2.2. Topiramate
10.2.2.3. Others
10.3. Market Size (US$ Mn) Forecast, By Route of Administration
10.3.1. Oral
10.3.2. Injectable
10.3.3. Others
10.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Others
10.5. Market Size by Value (US$ Mn) Forecast, By Country
10.5.1. Germany
10.5.2. France
10.5.3. U.K.
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Asia Pacific Anti-migraine Drugs Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, By Treatment
11.2.1. Abortive
11.2.1.1. Triptans
11.2.1.2. Ergot Alkaloids
11.2.1.3. Others
11.2.2. Prophylactic
11.2.2.1. Botulinum Toxin
11.2.2.2. Topiramate
11.2.2.3. Others
11.3. Market Size (US$ Mn) Forecast, By Route of Administration
11.3.1. Oral
11.3.2. Injectable
11.3.3. Others
11.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Others
11.5. Market Size by Value (US$ Mn) Forecast, By Country
11.5.1. India
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country
12. Latin America Anti-migraine Drugs Market Analysis and Forecast
12.1. Key Findings
12.2. Market Size (US$ Mn) Forecast, By Treatment
12.2.1. Abortive
12.2.1.1. Triptans
12.2.1.2. Ergot Alkaloids
12.2.1.3. Others
12.2.2. Prophylactic
12.2.2.1. Botulinum Toxin
12.2.2.2. Topiramate
12.2.2.3. Others
12.3. Market Size (US$ Mn) Forecast, By Route of Administration
12.3.1. Oral
12.3.2. Injectable
12.3.3. Others
12.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Others
12.5. Market Size by Value (US$ Mn) Forecast, By Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country
13. Middle East and Africa Anti-migraine Drugs Market Analysis and Forecast
13.1. Key Findings
13.2. Market Size (US$ Mn) Forecast, By Treatment
13.2.1. Abortive
13.2.1.1. Triptans
13.2.1.2. Ergot Alkaloids
13.2.1.3. Others
13.2.2. Prophylactic
13.2.2.1. Botulinum Toxin
13.2.2.2. Topiramate
13.2.2.3. Others
13.3. Market Size (US$ Mn) Forecast, By Route of Administration
13.3.1. Oral
13.3.2. Injectable
13.3.3. Others
13.4. Market Size (US$ Mn) Forecast, By Distribution Chanel
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Others
13.5. Market Size by Value (US$ Mn) Forecast, By Country
13.5.1. Saudi Arabia
13.5.2. South Africa
13.5.3. Israel
13.5.4. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. AstraZeneca Plc.
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Product Portfolio
14.2.1.3. SWOT Analysis
14.2.1.4. Financial Overview
14.2.1.5. Strategic Overview
14.2.2. Allergan Plc.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Product Portfolio
14.2.2.3. SWOT Analysis
14.2.2.4. Financial Overview
14.2.2.5. Strategic Overview
14.2.3. GlaxoSmithKline Plc.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Product Portfolio
14.2.3.3. SWOT Analysis
14.2.3.4. Financial Overview
14.2.3.5. Strategic Overview
14.2.4. Novartis AG
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Product Portfolio
14.2.4.3. SWOT Analysis
14.2.4.4. Financial Overview
14.2.4.5. Strategic Overview
14.2.5. Pfizer, Inc.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Product Portfolio
14.2.5.3. SWOT Analysis
14.2.5.4. Financial Overview
14.2.5.5. Strategic Overview
14.2.6. Valeant Pharmaceuticals International, Inc.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Product Portfolio
14.2.6.3. SWOT Analysis
14.2.6.4. Financial Overview
14.2.6.5. Strategic Overview
14.2.7. Teva Pharmaceutical Industries, Ltd.
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Product Portfolio
14.2.7.3. SWOT Analysis
14.2.7.4. Financial Overview
14.2.7.5. Strategic Overview
14.2.8. Eli Lilly & Company
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Product Portfolio
14.2.8.3. SWOT Analysis
14.2.8.4. Financial Overview
14.2.8.5. Strategic Overview
14.2.9. Merck & Co., Inc.
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Product Portfolio
14.2.9.3. SWOT Analysis
14.2.9.4. Financial Overview
14.2.9.5. Strategic Overview
14.2.10. Janssen Pharmaceutical Company (Johnson & Johnson)
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Product Portfolio
14.2.10.3. SWOT Analysis
14.2.10.4. Financial Overview
14.2.10.5. Strategic Overview
14.2.11. Endo Pharmaceutical Inc.
14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.11.2. Product Portfolio
14.2.11.3. SWOT Analysis
14.2.11.4. Financial Overview
14.2.11.5. Strategic Overview
14.2.12. Zosano Pharma Corporation
14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.12.2. Product Portfolio
14.2.12.3. SWOT Analysis
14.2.12.4. Financial Overview
14.2.12.5. Strategic Overview
14.2.13. Alder BioPharmaceutical, Inc.
14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.13.2. Product Portfolio
14.2.13.3. SWOT Analysis
14.2.13.4. Financial Overview
14.2.13.5. Strategic Overview
14.2.14. Avanir Pharmaceuticals, Inc.
14.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.14.2. Product Portfolio
14.2.14.3. SWOT Analysis
14.2.14.4. Financial Overview
14.2.14.5. Strategic Overview
14.2.15. Eisai Co., Ltd.
14.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.15.2. Product Portfolio
14.2.15.3. SWOT Analysis
14.2.15.4. Financial Overview
14.2.15.5. Strategic Overview
Table 01: Pipeline Analysis, Migraine Therapy Drugs (1/3)
Table 02: Pipeline Analysis, Migraine Therapy Drugs (2/3)
Table 03: Pipeline Analysis, Migraine Therapy Drugs (3/3)
Table 04: Pipeline Analysis, Migraine Therapy Devices
Table 05: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 06: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 07: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 08: Global New Chronic Constipation Therapies Market Size (US$) Forecast, 2017-2025
Table 09: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 10: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 11: Global Migraine Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 12: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 13: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 14: North America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 15: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 16: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: North America Migraine Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 19: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 20: Europe Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 21: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 22: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 23: Europe Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 24: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 25: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 26: Asia Pacific Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 27: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 28: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 29: Asia Pacific Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 30: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 31: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 32: Latin America Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 33: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 34: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 35: Latin America Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 36: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 37: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Abortive Treatment, 2015–2025
Table 38: Middle East & Africa Migraine Drugs Market Size (US$ Mn) Forecast, by Prophylactic Treatment, 2015–2025
Table 39: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 40: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 41: Middle East & Africa Migraine Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2015–2025